Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians ...
A 29-year-old woman was referred to Tufts Medical Center for undifferentiated bilateral anterior and intermediate uveitis.The ...
The MarketWatch News Department was not involved in the creation of this content. Vyome's offering is a first-of-its-kind in a broader $20B potential addressable ocular inflammation market VT-1908 ...
Hosted on MSN
Early detection is key to improving treatment of uveitis, a global leading cause of vision loss
New treatment guidance has been developed to help doctors tackle uveitis—one of the leading causes of vision loss. The new clinical guidance, by a team at the University of Bristol, aims to help ...
Significantly fewer patients in the fluocinolone acetonide intravitreal implant group experienced recurrence of uveitis at 6 months compared with the sham group. The Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback